Clinical Trial Update: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating olaparib for advanced or metastatic bladder cancer and other genitourinary tumors with DNA-repair gene changes has been susp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Genitourinary Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma | Phase 2 | Status: SUSPENDED